Human interleukin-2

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.


Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Human interleukin-2
Accession Number

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

  • IL-2
CAS number
Not Available


Not Available
Not Available
Mechanism of action
Not Available
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Not Available
Route of elimination
Not Available
Half life
Not Available
Not Available
Not Available
Affected organisms
Not Available
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Human interleukin-2.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Human interleukin-2.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Human interleukin-2.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Human interleukin-2.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
0CompletedDiagnosticStage IV Skin Melanoma1
1Active Not RecruitingTreatmentChronic Graft Versus Host Disease / Complications of Organ Transplant Stem Cells1
1Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
1Active Not RecruitingTreatmentNeuroblastomas1
1Active Not RecruitingTreatmentType 1 Diabetes Mellitus1
1CompletedPreventionAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Smith-Magenis Syndrome1
1CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Chronic myelogenous leukemia / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAdult Soft Tissue Sarcoma / Bone Cancer / Breast Cancer / Colorectal Cancers / Eye Cancer / Lung Cancers / Malignant Neoplasm of Colon / Melanoma / Ovarian Sarcoma / Rectal Carcinoma / Uterine Sarcoma1
1CompletedTreatmentCLDN18.2-positive Adenocarcinoma of Esophagus / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction / CLDN18.2-positive Gastric Adenocarcinoma1
1CompletedTreatmentFallopian Tube Cancer / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentGastrointestinal Metastatic Cancer1
1CompletedTreatmentHematologic Diseases1
1CompletedTreatmentHer2-Positive Breast Cancer / Non-Small Cell Lung Cancer Recurrent / Recurrent Breast Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor1
1CompletedTreatmentHodgkins Disease (HD) / Leukemias / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
1Not Yet RecruitingTreatmentCancer, Advanced / Mesothelioma, Malignant / PD-L1 negative / Progressive Disease1
1Not Yet RecruitingTreatmentSolid Tumor, Adult1
1RecruitingTreatmentClinical Stage IV Cutaneous Melanoma AJCC v8 / Clinical Stage IV Cutaneous Melanoma AJCC v8 (American Joint Committee on Cancer ) / Cutaneous Melanoma, Stage III / Cutaneous Melanoma, Stage IV / IL13RA2 Positive / Metastatic Melanoma / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IV Cutaneous Melanoma AJCC v81
1RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
1RecruitingTreatmentLung Cancers / Melanoma / Tumors, Solid1
1RecruitingTreatmentMetastatic Melanoma1
1TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1TerminatedTreatmentNeoplasms, Breast / Neoplasms, Kidney / Neoplasms, Lung / Sarcomas1
1TerminatedTreatmentNeoplasms, Kidney1
1WithdrawnTreatmentInvasive Bladder Cancer Stage IV1
1WithdrawnTreatmentMetastatic Renal Cell Carcinoma1
1, 2Active Not RecruitingTreatmentOvarian Cancer Metastatic1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentKidney / Malignancies1
1, 2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentMelanoma (Skin)1
1, 2CompletedTreatmentMetastatic Melanoma2
1, 2Not Yet RecruitingTreatmentAdvanced Malignant Solid Tumor1
1, 2Not Yet RecruitingTreatmentRecurrent Miscarriages1
1, 2Not Yet RecruitingTreatmentStage IV Adult Hodgkin Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Gastric Carcinoma / Stage IV Nasopharyngeal Carcinoma / Stage IV T-Cell Lymphoma1
1, 2RecruitingTreatmentLeukemia, B-Cell / Lymphoma, B-Cell1
1, 2RecruitingTreatmentMacrophage Activation Syndrome1
1, 2TerminatedTreatmentProstate Cancer1
1, 2TerminatedTreatmentRecurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
1, 2Unknown StatusTreatmentAlopecia Areata (AA)1
1, 2WithdrawnTreatmentHepatic Metastases / Lung Cancer Metastatic / Metastatic Melanoma / Tumors Metastatic to Brain1
1, 2WithdrawnTreatmentMelanoma / Renal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2Active Not RecruitingTreatmentEffects of Immunotherapy / Neoplasm, Residual / Neuroblastomas1
2Active Not RecruitingTreatmentMalignant Melanoma1
2Active Not RecruitingTreatmentMetastatic Melanoma1
2Active Not RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage I Non-Small Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentType 1 Diabetes Mellitus1
2CompletedNot AvailableAcute Myelogenous Leukaemia (AML)1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentBreast Cancer / Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentExtraocular Extension Melanoma / Recurrent Intraocular Melanoma1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections7
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMelanoma / Neoplasms Metastasis1
2CompletedTreatmentMetastatic Disease / Renal Cell Adenocarcinoma1
2CompletedTreatmentMyelodysplastic Syndrome1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentPrimary Sjögren's Syndrome1
2CompletedTreatmentProstatic Neoplasms1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRenal Cell Adenocarcinoma2
2CompletedTreatmentRheumatoid Arthritis1
2Not Yet RecruitingTreatmentHead Neck Tumors / Neuroendocrine Tumors / Rare Cancer / Soft Tissue Sarcoma (STS) / Vaccination1
2Not Yet RecruitingTreatmentInflammatory Myopathy1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
2Not Yet RecruitingTreatmentMetastatic Melanoma1
2Not Yet RecruitingTreatmentPemphigus Vulgaris (PV)1
2Not Yet RecruitingTreatmentPolymyalgia Rheumatica1
2Not Yet RecruitingTreatmentRelapsing Polychondritis1
2Not Yet RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2RecruitingPreventionAcute Graft-Versus-Host Disease1
2RecruitingTreatmentHigh Grade Ovarian Serous Adenocarcinoma / Metastatic Colorectal Adenocarcinoma / Oligometastasis / Ovarian Carcinosarcoma / Pancreatic Ductal Adenocarcinoma / Recurrent Colorectal Carcinoma / Recurrent Malignant Neoplasm / Recurrent Osteosarcoma / Recurrent Ovarian Carcinoma / Refractory Colorectal Carcinoma / Refractory Malignant Neoplasm / Refractory Osteosarcoma / Refractory Ovarian Carcinoma / Stage IV Colorectal Cancer AJCC v81
2RecruitingTreatmentNewly Diagnosed High Risk Neuroblastoma1
2RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML)1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Refractory Acute Myelogenous Leukemia1
2TerminatedTreatmentBreast Cancer1
2TerminatedTreatmentKidney Cancer Metastatic / Renal Cell Cancer Metastatic1
2TerminatedTreatmentLeukemia, Myelogenous, Acute1
2TerminatedTreatmentMelanoma Metastatic1
2TerminatedTreatmentMetastatic Colorectal Cancer (MCRC)1
2TerminatedTreatmentMetastatic Malignant Melanoma and Renal Cell Carcinoma1
2TerminatedTreatmentMetastatic Renal Cell Carcinoma1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2WithdrawnTreatmentMelanoma / Metastatic Kidney Cancer1
2WithdrawnTreatmentMetastatic Melanoma1
2, 3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2, 3RecruitingTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentMetastatic Renal Cell Carcinoma1
3CompletedTreatmentRenal Cell Adenocarcinoma1
3Unknown StatusPreventionHepatitis A / Human Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)2
4TerminatedOtherMetastatic Melanoma1
Not AvailableActive Not RecruitingTreatmentBeta Thalassemia Major1
Not AvailableCompletedPreventionSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableCompletedTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableNot Yet RecruitingTreatmentBreast Cancer / Lung Cancers / Malignant Pleural Effusions1
Not AvailableTerminatedPreventionLeukemias1
Not AvailableWithdrawnNot AvailableHormone Refractory Prostate Cancer1


Not Available
Not Available
Dosage forms
Not Available
Not Available
Not Available


Not Available
Experimental Properties
Not Available


Not classified

Drug created on May 20, 2019 08:31 / Updated on November 02, 2019 03:27